Literature DB >> 15879023

Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection.

John S Lambert1, Jack Moye, Susan F Plaeger, E Richard Stiehm, James Bethel, Lynne M Mofenson, Bonnie Mathieson, Jonathan Kagan, Howard Rosenblatt, Helene Paxton, Hildie Suter, Alan Landay.   

Abstract

This study of a subset of women and infants participating in National Institutes of Health Pediatric AIDS Clinical Trials Group protocol 185 evaluated lymphocyte phenotypic markers of immune activation and differentiation to determine their association with the likelihood of human immunodeficiency virus (HIV) transmission from the women to their infants and the potential for early identification and/or prognosis of infection in the infants. Lymphocytes from 215 human immunodeficiency virus type 1 (HIV)-infected women and 192 of their infants were analyzed by flow cytometry with an extended three-color panel of monoclonal antibodies. Women who did not transmit to their infants tended to have higher CD4+ T cells. Most notably, levels of total CD8+ T cells and CD8+ CD38+ cells made significant independent contributions to predicting the risk of mother-to-child transmission. Adjusting for HIV-1 RNA level at entry, a one percentage-point increase in these marker combinations was associated with a nine percent increase in the likelihood of maternal transmission. Total as well as naive CD4+ T cells were significantly higher in uninfected than infected infants. Total CD8+ cells, as well as CD8+ cells positive for HLA-DR+, CD45 RA+ HLA-DR+, and CD28+ HLA-DR+ were elevated in infected infants. Detailed immunophenotyping may be helpful in predicting which pregnant HIV-infected women are at increased risk of transmitting HIV to their infants. Increasing differences in lymphocyte subsets between infected and uninfected infants became apparent as early as six weeks of age. Detailed immunophenotyping may be useful in supporting the diagnosis of HIV infection in infants with perinatal HIV exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879023      PMCID: PMC1112077          DOI: 10.1128/CDLI.12.5.622-631.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  37 in total

1.  Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants.

Authors:  S Plaeger; S Bermudez; Y Mikyas; N Harawa; R Dickover; D Mark; M Dillon; Y J Bryson; P J Boyer; J S Sinsheimer
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). Study Group for Vertical Transmission.

Authors:  C Mazza; A Ravaggi; A Rodella; M Duse; D Padula; M Lomini; F Castelli; S Bresciani; A Albertini; E Cariani
Journal:  J Med Virol       Date:  1999-05       Impact factor: 2.327

3.  The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia.

Authors:  Celine M Radder; Dave L Roelen; Ellen M W van de Meer-Prins; Frans H J Claas; Humphrey H H Kanhai; Anneke Brand
Journal:  Am J Obstet Gynecol       Date:  2004-09       Impact factor: 8.661

4.  Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules.

Authors:  D Rigal; C Vermot-Desroches; S Heitz; J Bernaud; F Alfonsi; J C Monier
Journal:  Clin Immunol Immunopathol       Date:  1994-06

5.  Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS.

Authors:  T Calvelli; T N Denny; H Paxton; R Gelman; J Kagan
Journal:  Cytometry       Date:  1993-10

6.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

7.  Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

Authors:  E R Stiehm; J S Lambert; L M Mofenson; J Bethel; J Whitehouse; R Nugent; J Moye; M Glenn Fowler; B J Mathieson; P Reichelderfer; G J Nemo; J Korelitz; W A Meyer; C V Sapan; E Jimenez; J Gandia; G Scott; M J O'Sullivan; A Kovacs; A Stek; W T Shearer; H Hammill
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

8.  Lymphocyte subsets in healthy children during the first 5 years of life.

Authors:  T Denny; R Yogev; R Gelman; C Skuza; J Oleske; E Chadwick; S C Cheng; E Connor
Journal:  JAMA       Date:  1992-03-18       Impact factor: 56.272

9.  A phenotypic study of CD8+ lymphocyte subsets in infants using three-color flow cytometry.

Authors:  C Jennings; K Rich; J N Siegel; A Landay
Journal:  Clin Immunol Immunopathol       Date:  1994-04

10.  An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro.

Authors:  T Ichiyama; Y Ueno; H Isumi; A Niimi; T Matsubara; S Furukawa
Journal:  Inflamm Res       Date:  2004-05-12       Impact factor: 4.575

View more
  2 in total

1.  In-utero infection with HIV-1 associated with suppressed lymphoproliferative responses at birth.

Authors:  B Lohman-Payne; T Sandifer; M OhAinle; C Crudder; J Lynch; M M Omenda; J Maroa; K Fowke; G C John-Stewart; C Farquhar
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 2.  HIV vaccines in infants and children.

Authors:  John S Lambert
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.